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Sickle cell disease is a multi-system disease, associated with episodes of acute illness and 
progressive organ damage. Many mechanisms contribute to the complex pathophysiology of 
sickle cell disease. The production of excess free radicals causes damage to several organs 
including the blood, vascular endothelium and liver. The effect of chronic low-dose 
supplementation with vitamin C (300mg/day for 6 weeks in adults or 100mg/day for 6 weeks 
in children) or vitamin E (100 IU/day for 6 weeks in adults) or L-Arginine (1g/day for 6 weeks 
in adults) in ameliorating the pathophysiology and combating the deleterious effects of sickle 





Sickle cell disease (SCD) is a class of 
hemoglobinopathy, which results from a single 
mutation in the beta globin chain inducing the 
substitution of valine for glutamic acid at the sixth 
amino acid position (Stuart and Nigel, 2004). This 
mutation leads to the production of abnormal 
hemoglobin S (HbS). In addition to homozygous sickle 
cell disease (HbSS), other forms such as hemoglobin 
SC disease (HbSC) and hemoglobin Sβ thalassemia 
(HbSβthal) also exist (Hyacinth et al, 2011). It is not 
clear where the initial mutation occurred but it is 
generally believed that the initial mutation occurred in 
West Africa (Kan and Dozy, 1980). However, the gene 
has spread across the world through migration. The first 
publication of sickle cell disease was in 1910 by Dr 
Herrick in the USA. The ailment was identified by Dr. 
Earnest E. Irons (an intern) in 1904 who initially 
examined a patient, Walter Clement Noel, a dental 
student from Granada (Sergeant, 2001). 
The sickle cell disease is the first known human 
molecular disease (Sergeant, 2001) and its molecular 
pathology was established in 1949 by Linus Pauling 
(Bunn, 1997).  
 
The sickle cell disease is the first known human 
molecular disease (Sergeant, 2001) and its molecular 
pathology was established in 1949 by Linus Pauling 
(Bunn, 1997).  
Incidence of SCD in West, Central and East Africa is 
between 5 - 20%. The disease is less common in 
Northern and Southern Africa. Gene frequency is 
higher in low-lying, wet regions with a high prevalence 
of malaria (Diallo & Tchemia, 2001). In Africa, 
120,000 – 200,000 babies are born each year with the 
sickle cell gene (WHO, 1994) while in Nigeria, it is 
estimated that 45,000 – 90,000 new babies are born 
each year with the gene (Shenoy, 2007). In the USA, 
sickle cell disease is considered the most common 
hemoglobinopathy and it is estimated that about 
100,000 individuals suffer from the disease (Hassel, 
2010).  
Although there is no cure for SCD, several therapeutic 
strategies including antioxidant supplementation had 
been suggested (See Reviews by Hyacinth et al, 2011; 
Nur et al, 2011; Chirico and Pialoux, 2012; Imaga, 
2013). Non-enzymatic antioxidants like vitamin C, 
Vitamin E and arginine are found in food sources. Food 
sources of vitamin C include citrus fruits, red and green 
peppers, cabbage and spinach. Food sources of vitamin 
E include green leafy vegetables (such as pumpkin and 
spinach), tomatoes, sweet potatoes, and carrots. 
Arginine is a naturally occurring basic amino acid 
which participates in many important biochemical 
reactions associated with normal physiology. It is found 
in proteinous foods like meat, poultry, nuts and fish and 
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also in watermelon. Antioxidant supplementation is 
cheap and affordable especially in economically 
disadvantaged populations like Nigeria and may be 
helpful in the management of SCD (Hyacinth et al, 
2010). This paper reviews the effects of chronic, low 
dose supplementation with vitamin C, vitamin E or L-
Arginine on some aspects of the pathophysiology of the 
disease. 
 
Hypoxia and the generation of free radicals 
Hypoxia is the central or primary pathogenic event in 
SCD that causes intracellular polymerization of HbS. 
The effect of SCD on every part of the body stems from 
the fact that under hypoxic circumstances the red blood 
cells of a sufferer assumes a sickle shape in vivo. This 
renders the erythrocyte more viscous than normal 
blood. Increased blood viscosity decreases blood flow 
in the capillaries, terminal arterioles and veins leading 
to stasis. A vicious cycle is thus set up. The available 
oxygen is utilized by surrounding tissue, leucocytes and 
reticulocytes thus further increasing the level of 
hypoxia. The resulting hypoxia causes a worsening of 
the sickling process causing the production of more 
sickle cells. Sickle red blood cells are more fragile than 
normal erythrocytes. They easily undergo phagocytosis 
and are also more easily removed from circulation. The 
increased destruction of the cells results in chronic 
anaemia and hemolytic-type jaundice. 
The RBC reoxygenation phase is a major source of free 
radical production in SCD. Repeated cycles of sickling 
and unsickling result in the production of irreversibly 
sickle cells. These cells play a role in the pathogenesis 
of sickle cell crisis (Dean & Schechter, 1978). The 
irreversibly sickle cells have increased intracellular 
viscosity due to their elevated hemoglobin 
concentration (Natta et al, 1980). The increased 
viscosity and increased membrane rigidity decrease 
blood flow in the capillaries, terminal arterioles and 
veins leading to stasis.  
During the period of reoxygenation, normal RBCs can 
generate a significant amount of superoxide due to an 
electron transfer between the heme iron and oxygen. In 
the presence of oxygen, heme auto-oxidizes inducing 
methemoglobin and superoxide formation. Although 
both hemoglobin A (HbA) and hemoglobin S (HbS) 
blood have a tendency to auto-oxidize into 
methemoglobin and superoxide (Aslan et al, 2000; 
Conran et al, 2009), HbS blood has been shown to 
auto-oxidize 1.7 times faster than HbA blood (Wood et 
al, 2008; Hebbel et al, 1998). Unlike HbA, which can 
counter this reaction to form harmless byproducts, HbS 
can become overwhelmed by the continual source of 
superoxide (O2-) and, via its dismutation, hydrogen 
peroxide (H2O2) (Aslan et al, 2000). The formation of 
H2O2, when exposed to methemoglobin, decomposes 
hemoglobin and releases iron. The iron can then react 
with remaining H2O2 to further produce hydroxyl 
radicals (OH-), the most reactive and harmful of the 
reactive species (Aslan et al, 2000). Sickle cells 
ultimately generate about twofold greater quantities of 
superoxide, hydrogen peroxide and hydroxyl radicals 
than HbA (Amer et al, 2006). These free radicals thus 
constitute oxidative stress burden and cause or are 
involved in multiple pathophysiologic mechanisms 
such as accelerated hemolysis (Krajewski et al, 2008), 
endothelial damage (Kato et al, 2009; Hebbel et al, 
2004), reduced NO bioavailability (Sydow and Munzel, 
2003; Beckman and Koppenol, 1996), and 
hypercoagulability (Singer and Ataga, 2008). These 
contribute to vaso-occlusion and damage to virtually 
every organ of the body (Nur et al, 2001; Morris et al, 
2008). Sickle cell disease is therefore characterized by 
lifelong continuous oxidative stress which results from 
an imbalance between oxidants and antioxidants in 
favor of the oxidants. 
 
Oxidative stress burden and response to 
antioxidant supplementation  
The body's defense mechanisms against reactive 
oxygen species (ROS) include enzymatic and non-
enzymatic systems. The enzymatic systems include 
catalase (CAT), superoxide dismutase (SOD), 
glutathione peroxidase (GPX), and nitric oxide (NO) 
and heme oxygenease-1. The nonenzymatic 
antioxidants which scavenge free radicals include 
ascorbic acid, tocopherols, reduced glutathione (GSH), 
carotenoids, lipoic acid, ubiquinols, selenium, 
riboflavin, zinc, carotenoids, and uric acid as well as 
metal-binding proteins. (Chirico and Pialoux, 2012).
  
Increased production of oxidants and/or decreased 
availability of antioxidants trigger(s) a cascade of 
oxidative reactions damaging lipids, proteins, and DNA 
ultimately leading to premature cell death (Nur et al, 
2011). Measurement of malondiadehyde (MDA) levels 
in blood had been used as an index of free radical 
generation. On the other hand, measurement of blood 
levels of antioxidant enzymes or non-enzymatic agents 
gave an indication of the ability of the subject to 
withstand the effects oxidative stress (El-Ghamrawy et 
al 2014; Jaja et al, 2013; Jaja et al, 2016).   
 
Plasma levels of malondialdehyde (MDA), an index of 
free radical generation, had been shown to be higher in 
HbSS than in HbAA subjects (Titus et al, 2004; El-
Ghamrawy et al 2014; Jaja et al, 2013; Jaja et al, 2016). 
Gbenebitse et al, (2005) investigated the effects of 
vitamin E supplementation on plasma vitamin E level, 
lipid peroxidation status, forearm blood flow and 
forearm vascular resistance in adult sickle cell anemia 
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subjects. Results showed that supplementation 
increased plasma vitamin E level and forearm blood 
flow but reduced forearm vascular resistance and lipid 
peroxidation status. Change in plasma vitamin E level 
correlated positively with change in forearm blood flow 
(r=0.8; p=0.006) and negatively with lipid peroxidation 
(r=-0.8; p=0.003). This showed that a reduction in lipid 
peroxidation level with vitamin E supplementation 
accounted for the increase in forearm blood flow in 
these subjects. 
Total antioxidant levels are depressed in SCD sufferers 
(Fasola et al, 2009; Kehinde et al, 2015). Fasola et al, 
(2009) showed that total antioxidant status (TAS) levels 
were about 50% lower in the SCA patients compared 
with NSCA counterparts. Among SCA patients studied, 
57.1% of those with TAS levels less than 1.00 mmol/L 
had bone pain crisis more than 3 times in the preceding 
year, compared with 16% in those with TAS levels 
greater than 1.00 mmol/L. Total leukocyte count and 
platelets were also significantly higher in the SCA 
patients than controls. (Fasola et al 2009). Plasma 
vitamin C or E had also been shown to be depressed in 
HbSS subjects and had been attributed to increased 
utilization of the vitamins or to increased renal loss 
(Jaja, et al, 2002; Hyacinth et al, 2011).  
Plasma l-arginine (also an antioxidant) concentration 
had also been shown to be lower in HbSS subjects than 
in their HbAA counterparts (Lopez et al, 2003; Scavella 
et al, 2010; Jaja et al, 2016). L-Arginine is the substrate 
for nitric oxide (NO) synthesis and in SCD increased 
NO consumption by cell-free haemoglobin (Reiter et al, 
2003) and reactive oxygen species (Morris et al, 2005) 
lead to decreased NO bioavailability (Reiter et al, 2003; 
Gladwin et al, 2003). Low arginine bioavailability had 
been linked with early mortality in adult sickle cell 
disease sufferers (Morris et al, 2005).  
 
Micronutrients and antioxidant supplementation. 
Trace metals are required as co-factors for efficient 
functioning of antioxidants which are present as 
metallo-enzymes or metallo-proteins. Superoxide 
dismuthase requires copper, zinc and manganese as 
cofactors, while catalase requires iron as a cofactor to 
catalyse the decomposition of hydrogen peroxide 
(H2O2) to water and oxygen. Glutathione peroxidase 
requires selenium as a cofactor and catalyses the 
degradation of H2O2 and hydro-peroxides at the 
expense of reduced glutathione (GSH) (Hyacinth et al, 
2010).  
Trace metals levels in blood had been reported as 
similar (Kehinde et al, 2010), lower (Olaniyi et al, 
2010) or higher (Akenami et al, 1999) in HbSS subjects 
in the steady state when compared to their HbAA 
counterparts. Also, Kehinde et al, (2010) reported that 
plasma levels of Cu++, Zn++ or Mn++ in HbSS subjects 
in the acute phase or during pain crises were higher 
than those of HbAA subjects or HbSS subjects in the 
steady state. However, Temiye et al, (2011) had shown 
that in HbSS children in painful crises, serum Zn++ 
level was lower than in HbAA children. They had 
suggested that painful crisis in SCA may exert greater 
demand for zinc utilization in children with SCA 
thereby resulting in lower serum levels. 
Ogungbemi (2014) had shown that arginine 
supplementation caused increases in serum levels of 
Zn++ and Cu++ in HbAA and HbSS subjects. The effect 
on serum Mn++ was similar in both groups of subjects. 
Greater increases were seen in the HbSS than in the 
HbAA group (except for Cu++). It is not clear how 
arginine supplementation increased the serum levels of 
the trace metals. However, since the sources of the 
trace metals are dietary it is likely that arginine may 
have enhanced intestinal absorption of these trace 
metals from food. Ogungbemi (2014) also 
demonstrated significant and positive correlations 
between change in plasma arginine (∆[R]) and change 
in each of the trace metals levels and also between ∆[R] 
and change in the various antioxidant enzymes levels 
suggesting that increased arginine levels resulted in 
elevated levels of trace metals and antioxidant 
enzymes. In addition, the study also demonstrated a 
significant and positive correlation between change in 
each of the antioxidant enzymes levels and change in 
each of the trace metals levels. The study also showed 
that the correlation coefficients (r) between change in 
measured antioxidant enzymes and change in trace 
metal levels were higher in HbSS than in their HbAA 
counterparts. Taken together, the study showed a 
relationship between serum trace metals concentrations 
and plasma antioxidant enzymes levels in the HbSS 
subjects.   
 
Effect of antioxidant supplementation on 
haematological parameters. 
Sickle cell disease subjects exhibit an elevated WBC, 
percent irreversibly sickle cells and platelet count and a 
reduced RBC count, hemoglobin concentration and 
hematocrit (Natt et al, 1980). Raised WBC count 
suggests disease severity. They could cause tissue 
damage and inflammatory reaction in vascular 
endothelium, increase expression of ligands for 
adhesion molecules on blood cells and can aggregate 
with other blood cells to cause vaso-occlusion (Okpala, 
2004). On their own part, activated platelets secrete 
ADP which cause adherence to sickle erythrocytes 
contributing to platelet plug and formation of 
microvascular obstruction (Villagra et al 2007). The 
lower RBC, [Hb] and Hct values seen in the SCA 
subjects are a direct consequence of the destruction of 
RBC seen in this condition (Jaja et al, 2000). 
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In HbSS subjects, oral, low-dose (300mg/day for adults 
and 100mg/day for children) supplementation with 
vitamin C (Jaja et al, 2000; 2002b), vitamin E (Jaja et 
al, 2001) or l-arginine (Kehinde et al, 2015) for 6 
weeks reduced mean corpuscular haemoglobin 
concentration (MCHC), percent of irreversibly sickle 
cells (%ISC) and also had a membrane stabilizing 
effect on the red blood cell.  
 
Lower blood pressures in sickle cell disease 
Studies in the United States of America, (Johnson & 
Giorgio, 1981, Saborio & Scheinmam 1999) and 
Nigeria (Jaja et al 2000) have shown that sickle cell 
disease patients have lower blood pressures than the 
general population. The mean blood pressures reported 
by Johnson & Giorgio (1981) were 116/70 mmHg 
while that reported by Jaja and associates (2000) were 
109/65 mmHg. Furthermore, it had been reported in the 
USA that whereas the incidence of hypertension in the 
black population is about 29% (Johnson & Giorgio, 
1981, Saborio & Scheinmam 1999), the incidence of 
hypertension in SCD patients is between 2 and 6%. 
Thus, blood pressure values that could be considered as 
normal or slightly elevated in healthy individuals may 
have serious cardiovascular and renal consequences in 
sickle cell disease patients (Saborio & Scheinmam 
1999). Although several reasons have been given for 
the lower blood pressures seen in sickle cell anaemia, 
the exact mechanism is not clear. Some of the reasons 
given include a renal tubular defect responsible for 
increased sodium and water excretion (Johnson & 
Giorgio, 1981) or a defect in the vascular tone (Hatch, 
1989). A third reason is a reduced peripheral resistance 
at the arteriolar level resulting from altered vascular 
reactivity to circulating vascular hormones like nitric 
oxide (Nath et al 2000). Using the transgenic sickle 
mouse model, Kaul et al (2000) had suggested that the 
microcirculatory flow abnormalities in transgenic sickle 
mouse could lead to chronic tissue hypoxia that triggers 
vascular tone modifications secondary to chronic 
increase in NOS/NO activity. Thus the elevated 
NOS/NO activity results in systemic hypotension 
associated with a depressor effect on the vascular tone. 
Vitamin C supplementation in adult or paediatric HbSS 
subjects (Jaja et al, 2000, 2002) reduced while vitamin 
E (Jaja et al, 2001; 2003) or l-arginine (Ogungbemi et 
al, 2013) supplementation had little or no effect arterial 
blood pressure.  
 
Abnormal autonomic cardiovascular response in 
sickle cell disease. 
Sufferers of SCD have an abnormal autonomic 
cardiovascular function (Romero-Vecchione, 1995) by 
exhibiting a blunted autonomic cardiovascular response 
to change in posture (Jaja et al., 2008; Ogungbemi et al, 
2013) which may result in sudden death (Romero-
Mestre et al., 1997). Jaja et al, (2008) showed that 
change in posture from lying to an upright posture 
elicited significantly higher tachycardia and myocardial 
oxygen demand (estimated by the rate pressure product; 
RPP) in non sickle cell disease (NSCD) than in SCD 
subjects. The greater increase in RPP seen in the NSCA 
subjects was attributed to the greater increase in their 
heart rate response to change in posture. The blunted 
reflex responses to change in posture seen in the SCA 
subjects showed that sickle cell disease subjects possess 
an abnormal autonomic cardiovascular function. 
Chronic low-dose vitamin C (300mg/day for 6 wks) or 
L-Arginine (1g/day for 6wks) supplementation 
normalized the blunted hemodynamic changes 
associated with posture adjustments in HbSS subjects 
(Jaja et al, 2008; Ogungbemi et al, 2013). The effect of 
L-arginine was attributed to elevated nitric oxide 
metabolites (NOX) elicited by arginine supplementation 
(Ogungbemi et al, 2013).  
 
Haemodynamic responses to antioxidant 
supplementation. 
Various studies have shown the interaction between 
sickle red cells and vascular endothelium, with 
researchers demonstrating that almost all major 
adhesion pathways are involved in this interaction 
(Hebbel et al, 1980; Barabino et al, 1987). Carotid 
endothelial damage results in plaque formation, which, 
when detected sub-clinically, enables early 
intervention, thereby preventing stenosis, infarction, 
and stroke (Adams et al, 1997). Olowoyeye et al, 
(2011) compared the effects of chronic, oral, low-dose 
vitamin C supplementation on peak systolic velocity 
(PSV), end-diastolic velocity (EDV), resistivity index 
(RI), intima-media thickness (IMT), and cross-sectional 
diameter (CSD) of the common carotid arteries of 
HbSS patients with HbAA subjects. Measurements 
were made using a duplex sonographic scanner (Aloka 
ProSound SSD-3500; Aloka, Wallingford, Connecticut) 
with a high-frequency (5–10 MHz), linear-array 
transducer. Results showed that in the pre-
supplementation phase, CSD and EDV were 
significantly higher and RI was significantly lower in 
the HbSS subjects than in the HbAA subjects. The 
changes brought about by vitamin C supplementation 
were more manifest in HbSS than in HbAA subjects. 
Vitamin C supplementation had a slight effect on all the 
measured parameters in the HbAA subjects but caused 
an increase in PSV, EDV and RI in HbSS subjects.  
Using the same dose and duration, Jaja et al (2002) had 
earlier shown that vitamin C supplementation or 
warmth (40OC) decreased arterial blood pressure, 
forearm vascular resistance but increased forearm 
blood flow in HbSS subjects. Pretreatment with vitamin 
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C enhanced the vasodilator effect of warmth. Vitamin 
C is known to reduce irreversibly sickle cells (Jaja et al, 
2000) which may in turn cause a decrease in blood 
viscosity and contributing to the increase in blood flow 
velocity (Olowoyeye et. al, 2011). 
 
Antioxidants and liver function 
In sickle cell disease (SCD) decreased liver function by 
adulthood had been attributed to acute and /or chronic 
ischaemia in the liver which may result in liver 
dysfunction (Charlotte et al, 1995). Liver dysfunction 
results in elevated liver enzymes (Kehinde et al, 2010; 
Pandey et al, 2012; Jaja et al, 2013; 2016).  Liver 
enzymes, alanine aminotransaminase (ALT), aspartate 
amino-tranaminase (AST) and alkaline phosphatase 
(ALP) had been shown to be elevated in HbSS subjects 
in crises (Kehinde et al, 2010) and in the steady state 
(Jaja et al, 2013). The elevated levels of these liver 
enzymes were however higher in subjects in crises than 
those in the steady state or non sickle cell sufferers 
(Kehinde et al, 2010). Elevated AST and ALT levels 
had been linked to damage to hepatic cells and 
hemolysis (Nsiah et al, 2011; Pandey et al, 2012) while 
elevated ALP had been related to destruction of the bile 
duct or bone associated with vaso occlusive crises 
resulting in delayed growth (Kotila et al, 2005).  
 
In the steady state, vitamin C supplementation caused a 
reduction in the elevated plasma liver enzymes and 
malondialdehyde (MDA) levels and an elevation in 
plasma catalase level (Jaja et al, 2013). The combined 
effect of elevation of antioxidant enzyme (catalase) 
activity and reduction in MDA level by vitamin C 
suggests that reduced oxidative stress burden may 
account for the reduction in plasma liver enzymes 
levels (an indication of improved liver function) in 
these subjects. 
In another study, Jaja et al, (2016) showed that arginine 
caused greater percent reductions in ALT and AST in 
HbSS than in HbAA subjects. It also caused greater 
percent increases in plasma arginine concentration 
([R]), and plasma nitric oxide metabolites concentration 
([NOX]) in HbSS than in HbAA subjects. Reductions in 
[MDA] were similar in both groups. The study thus 
showed that although l-arginine supplementation 
improved liver function, oxidative stress, [R] and NOX 
levels in both groups of subjects the responses in HbSS 
subjects were more sensitive than in HbAA subjects. 
 
Some other therapeutic strategies 
Currently, there is no cure for sickle cell disease. 
However, hydroxyurea which is the approved therapy 
for the management of the disease may have certain 
benefits and drawbacks. It decreases the polymerization 
rate of Hb S by increasing Hb F concentration 
(Raghupathy and Billet, 2009). Although it is 
considered safe in the short term, it may possess 
myelosuppresive effects on leucocytes and platelets and 
does not prevent stroke even with elevation of Hb F 
levels (Atweh and Schechter, 2001).  
Nitric oxide (NO) inhalation had also been suggested. 
In transgenic sickle mice, nitric oxide inhalation 
reduced red cell density, increased perfusion and 
decreased lung injury, microvascular vaso-occlusion 
and mortality (Martinez-Ruiz et al, 2001). However, 
clinical studies on nitric oxide inhalation in humans had 
provided divergent results. While inhaled NO 
significantly reduced pain scores in adult patients 
(Head et al, 2010) and children with acute vaso 
occlusive (VOC) pain (Weiner et al, 2003), Gladwin et 
al. (2011) showed that inhaled NO did not reduce VOC 
pain severity in SCD. Inspite of these controversies, 
inhaled NO is cumbersome and may have side effects 
that require close monitoring in an acute care setting, 
thus limiting its application (Morris et al, 2000).  
Sildenafil was also used to amplify the effect of 
endogenous NO. Sildenefil inhibits the breakdown of 
its downstream signal transduction mediator, cyclic 
GMP (Machado et al, 2005) thus amplifying the effect 
of endogenous NO.  However, the use of sildenafil has 
been discontinued because of safety concerns 
(Machado et al, 2011).  
Stem cell transplantation (Piel et al, 2013) and gene 
therapy (Townes, 2008) are novel methods of treatment 
that are either in their experimental stages or 
considered very expensive and sophisticated for the 




In conclusion, SCD is characterized by increased 
generation of ROS resulting in oxidative damage of 
various cell types and playing a significant role in the 
development of SCD related organ complications. The 
use of antioxidant supplementation has shown some 
promise as potential therapeutic agent. By limiting the 
production of ROS, many of the complications of SCD 
could be diminished. In endemic regions like sub-
Sahara Africa, where the economy and technology are 
weak, effective therapy must be affordable and 
available. Antioxidant (vitamin C, E or L-Arginine) 
therapy is cheap and affordable. Further studies are still 
required to investigate the effect of antioxidants on 
glucose metabolism, haemostasis and possible role in 
the prevention of stroke in SCD.  
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